These results are especially meaningful for the monitoring of treatment with molecular targeted agents, such as anti-EGFR antibodies for colorectal cancer and EGFR-tyrosine kinase inhibitors for lung cancer [29–31]. This evidence concerns the gene EGFR and lung cancer.